Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 May;27(5):688–691. doi: 10.1128/aac.27.5.688

Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

S M Smith, R H Eng
PMCID: PMC180133  PMID: 3160301

Abstract

Ciprofloxacin, a carboxy quinolone antibiotic with a broad spectrum of activity, was tested against 54 strains of methicillin-resistant Staphylococcus aureus. The ciprofloxacin MICs for 50 and 90% of the isolates were 0.25 and 0.5 micrograms/ml, respectively, and its MBC for 90% of the isolates was 1.0 microgram/ml. Killing kinetic studies were conducted in vitro with ciprofloxacin and vancomycin individually and in combination. The results of these studies showed that ciprofloxacin at 2 micrograms/ml and vancomycin at 10 micrograms/ml decreased the number of organisms by approximately 1.5 log10 after 6 h. The combination of ciprofloxacin plus vancomycin did not alter the rate of killing over that achieved by ciprofloxacin alone. The in vitro killing of resistant staphylococci was rapid, and the potential use of ciprofloxacin for infections caused by methicillin-resistant S. aureus should be further explored.

Full text

PDF
688

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Courvalin P., Chabbert Y. A. Methicillin-resistant staphylococcemia: bacteriological failure of treatment with cephalosporins. Antimicrob Agents Chemother (Bethesda) 1970;10:280–285. [PubMed] [Google Scholar]
  2. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983 Apr;2(2):111–115. doi: 10.1007/BF02001575. [DOI] [PubMed] [Google Scholar]
  3. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eng R. H., Parken P., Tecson-Tumang F. Penetration of antibiotics into vegetation of heart valves: a mathematical model. Chemotherapy. 1982;28(6):421–427. doi: 10.1159/000238133. [DOI] [PubMed] [Google Scholar]
  5. Eng R. H., Smith S. M., Buccini F. J., Cherubin C. E. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother. 1985 Feb;15(2):201–207. doi: 10.1093/jac/15.2.201. [DOI] [PubMed] [Google Scholar]
  6. Eng R. H., Smith S. M., Tillem M., Cherubin C. Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection. Arch Intern Med. 1985 Jan;145(1):146–148. doi: 10.1001/archinte.145.1.146. [DOI] [PubMed] [Google Scholar]
  7. Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fekety R. Vancomycin. Med Clin North Am. 1982 Jan;66(1):175–181. doi: 10.1016/s0025-7125(16)31451-1. [DOI] [PubMed] [Google Scholar]
  9. Kind A. C., Tupasi T. E., Standiford H. C., Kirby W. M. Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch Intern Med. 1970 Apr;125(4):685–690. [PubMed] [Google Scholar]
  10. Li K., Farmer J. J., 3rd, Coppola A. A novel type of resistant bacteria induced by gentamicin. Trans N Y Acad Sci. 1974 May;36(5):396–415. doi: 10.1111/j.2164-0947.1974.tb01592.x. [DOI] [PubMed] [Google Scholar]
  11. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]
  12. Sugarman B., Pesanti E. Treatment failures secondary to in vivo development of drug resistance by microorganisms. Rev Infect Dis. 1980 Mar-Apr;2(2):153–168. doi: 10.1093/clinids/2.2.153. [DOI] [PubMed] [Google Scholar]
  13. Watanakunakorn C. Treatment of infections due to methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):376–378. doi: 10.7326/0003-4819-97-3-376. [DOI] [PubMed] [Google Scholar]
  14. Wenzel R. P. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):440–442. doi: 10.7326/0003-4819-97-3-440. [DOI] [PubMed] [Google Scholar]
  15. Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES